Alphabet’s AI drug discovery platform Isomorphic Labs raises $600M from Thrive
Isomorphic Labs, an AI drug discovery platform from DeepMind, has secured $600 million in funding led by Thrive Capital to enhance its AI development.
MAIN POINTS
- Isomorphic Labs, a spin-off from DeepMind, focuses on AI-driven drug discovery.
- The platform raised $600 million in its first external funding round.
- Thrive Capital led the funding, with participation from GV and Alphabet.
- The funds aim to accelerate Isomorphic's AI development efforts.
TAKEAWAYS
- Isomorphic Labs is expanding its capabilities with significant financial backing.
- The involvement of major investors highlights confidence in AI's role in drug discovery.
- This funding marks a pivotal moment for Isomorphic Labs' growth trajectory.
- The collaboration between tech and healthcare sectors is increasingly prominent.